

## Predictive Biomarkers for Endocrine Therapy

Roseweir, Antonia K; Bennett, Lindsay; Dickson, Ashley; Cheng, Kelvin; Quintayo, Mary-Anne; Bayani, Jane; McMillan, Donald C; Horgan, Paul G; van de Velde, Cornelis J H; Seynaeve, Caroline; Hasenburg, Annette; Kieback, Dirk G; Markopoulos, Christos; Dirix, Luc Y; Rea, Daniel; Mallon, Elizabeth A; Bartlett, John M S; Edwards, Joanne

DOI:

[10.1093/jnci/djx255](https://doi.org/10.1093/jnci/djx255)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Roseweir, AK, Bennett, L, Dickson, A, Cheng, K, Quintayo, M-A, Bayani, J, McMillan, DC, Horgan, PG, van de Velde, CJH, Seynaeve, C, Hasenburg, A, Kieback, DG, Markopoulos, C, Dirix, LY, Rea, D, Mallon, EA, Bartlett, JMS & Edwards, J 2018, 'Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial', *Journal of the National Cancer Institute*, vol. 110, no. 6, pp. 616-627. <https://doi.org/10.1093/jnci/djx255>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

Checked for eligibility: 28/06/2018

This is a pre-copyedited, author-produced version of an article accepted for publication in JNCI: Journal of the National Cancer Institute following peer review. The version of record: Antonia K Roseweir, Lindsay Bennett, Ashley Dickson, Kelvin Cheng, Mary-Anne Quintayo, Jane Bayani, Donald C McMillan, Paul G Horgan, Cornelis J H van de Velde, Caroline Seynaeve, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, Luc Y Dirix, Daniel W Rea, Elizabeth A Mallon, John M S Bartlett, Joanne Edwards; Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial, JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, 1 June 2018, Pages 616–627 is available online at: <https://doi.org/10.1093/jnci/djx255>

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.


Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.


When citing, please reference the published version.

### **Take down policy**


While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.




**A****Exemestane**Number of patients  
(number censored)


	0	2	4	6	8	10
Negative	791 (0)	745 (2)	680 (7)	566 (78)	461 (157)	236 (372)
Positive	744 (0)	701 (6)	651 (10)	541 (70)	436 (167)	187 (407)

**Tamoxifen followed by exemestane**Number of patients  
(number censored)


	0	2	4	6	8	10
Negative	788 (0)	725 (5)	651 (16)	526 (75)	401 (175)	201 (370)
Positive	701 (0)	640 (6)	590 (14)	518 (63)	406 (150)	181 (372)

**B**Number of patients  
(number censored)


	0	2	4	6	8	10
Both negative	470 (0)	441 (1)	394 (6)	334 (40)	286 (73)	167 (185)
One positive	885 (0)	834 (6)	772 (9)	636 (91)	503 (207)	211 (489)
Both positive	97 (0)	93 (0)	91 (1)	76 (9)	58 (27)	21 (62)

Number of patients  
(number censored)


	0	2	4	6	8	10
Both negative	503 (0)	459 (3)	407 (8)	324 (39)	265 (83)	154 (190)
One positive	826 (0)	756 (6)	699 (17)	600 (83)	462 (190)	207 (442)
Both positive	97 (0)	94 (2)	88 (3)	81 (9)	54 (34)	11 (76)

**C**Number of patients  
(number censored)


	0	2	4	6	8	10
All negative	445 (0)	418 (1)	375 (6)	318 (38)	271 (70)	160 (174)
One/two positive	874 (0)	825 (6)	762 (9)	635 (86)	506 (199)	212 (483)
All positive	133 (0)	125 (0)	120 (1)	93 (16)	70 (38)	27 (79)

Number of patients  
(number censored)

	0	2	4	6	8	10
All negative	485 (0)	443 (3)	396 (8)	314 (37)	254 (81)	147 (185)
One/two positive	808 (0)	738 (6)	676 (17)	581 (80)	454 (179)	205 (425)
All positive	133 (0)	28 (2)	122 (3)	110 (14)	73 (47)	20 (98)




### A Negative expression




Number of patients (number censored)	Follow-up for recurrence (years)					
	0	2	4	6	8	10
Exemestane	791 (0)	745 (2)	680 (7)	566 (78)	461 (157)	236 (372)
Tamoxifen	788 (0)	725 (5)	651 (16)	526 (75)	401 (175)	201 (370)

### Positive expression




Number of patients (number censored)	Follow-up for recurrence (years)					
	0	2	4	6	8	10
Exemestane	744 (0)	701 (6)	651 (10)	551 (70)	436 (167)	187 (407)
Tamoxifen	701 (0)	640 (6)	590 (14)	518 (63)	406 (150)	181 (372)

### B



Number of patients (number censored)	Follow-up for recurrence (years)					
	0	2	4	6	8	10
Exemestane	570 (0)	537 (2)	484 (7)	405 (54)	352 (88)	204 (221)
Tamoxifen	584 (0)	533 (3)	473 (9)	377 (49)	307 (102)	178 (271)



Number of patients (number censored)	Follow-up for recurrence (years)					
	0	2	4	6	8	10
Exemestane	346 (0)	332 (0)	315 (4)	258 (40)	185 (108)	51 (237)
Tamoxifen	322 (0)	301 (4)	279 (8)	245 (33)	174 (93)	51 (213)